US4742057A
(en)
*
|
1985-12-05 |
1988-05-03 |
Fujisawa Pharmaceutical Co., Ltd. |
Antiallergic thiazole compounds
|
FR2608157B1
(fr)
*
|
1986-12-11 |
1989-09-08 |
Roussel Uclaf |
Nouveaux derives de l'azaspirodecane, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant et intermediaires
|
US4999356A
(en)
*
|
1987-08-07 |
1991-03-12 |
Hoechst-Roussel Pharmaceuticals, Inc. |
1-phenyl-3-(1-piperazinyl)-1H-indazoles
|
GB8719167D0
(en)
*
|
1987-08-13 |
1987-09-23 |
Glaxo Group Ltd |
Chemical compounds
|
PT88255B
(pt)
*
|
1987-08-13 |
1995-03-01 |
Glaxo Group Ltd |
Processo para a preparacao de derivados do indole
|
FR2621588B1
(fr)
*
|
1987-10-08 |
1991-05-24 |
Roussel Uclaf |
Nouveaux derives de la 1,1-dioxo 1,2-benzoisothiazol 3-one, leur procede de preparation et leur application comme medicaments
|
FR2621586B1
(fr)
*
|
1987-10-08 |
1990-02-02 |
Roussel Uclaf |
Nouveaux derives de l'azapirodecane, leur procede de preparation et leur application comme medicaments
|
DK733788A
(da)
*
|
1988-01-14 |
1989-07-15 |
Fujisawa Pharmaceutical Co |
Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf
|
FR2633928B1
(fr)
*
|
1988-07-07 |
1991-04-26 |
Rhone Poulenc Sante |
Derives de (aza)naphtalenesultame, leurs procedes de preparation et les medicaments les contenant
|
FR2643265B1
(fr)
*
|
1989-02-20 |
1991-04-26 |
Rhone Poulenc Sante |
Derives de (aza)naphto(1,8-cd)isothiazole dioxyde-1,1 leurs procedes de preparation et les medicaments les contenant
|
IL90858A
(en)
*
|
1988-07-07 |
1994-08-26 |
Rhone Poulenc Sante |
History (Aza) Naftalensultam, their preparation and preparations containing them
|
GB8819024D0
(en)
*
|
1988-08-10 |
1988-09-14 |
Glaxo Group Ltd |
Chemical compounds
|
US5238945A
(en)
*
|
1989-04-11 |
1993-08-24 |
H. Lundbeck A/S |
Method of treating psychoses
|
GB8908085D0
(en)
*
|
1989-04-11 |
1989-05-24 |
Lundbeck & Co As H |
New therapeutic use
|
FR2656306A1
(fr)
*
|
1989-12-26 |
1991-06-28 |
Rhone Poulenc Sante |
Derives heterocycliques, leur preparation et les medicaments les contenant.
|
EP0429341A3
(en)
*
|
1989-11-20 |
1991-11-13 |
Rhone-Poulenc Sante |
Heterocyclic derivatives, their preparation and pharmaceuticals containing them
|
FR2663635A2
(fr)
*
|
1989-12-26 |
1991-12-27 |
Rhone Poulenc Sante |
Derives heterocycliques, leur preparation et les medicaments les contenant.
|
FR2654729B1
(fr)
*
|
1989-11-20 |
1992-02-07 |
Rhone Poulenc Sante |
Derives de la piperidine, leur preparation et les medicaments les contenant.
|
DK152090D0
(da)
*
|
1990-06-22 |
1990-06-22 |
Lundbaek A S H |
Piperidylsubstituerede indolderivater
|
DK158590D0
(da)
*
|
1990-07-02 |
1990-07-02 |
Lundbeck & Co As H |
Indolderivater
|
US5322851A
(en)
*
|
1990-07-02 |
1994-06-21 |
H. Lundbeck A/S |
Indole derivatives
|
DK181190D0
(da)
*
|
1990-07-30 |
1990-07-30 |
Lundbeck & Co As H |
3-aryl-indol- eller 3-aryl-indazolderivater
|
DK238190D0
(da)
*
|
1990-10-03 |
1990-10-03 |
Lundbeck & Co As H |
Depotderivater
|
US5643784A
(en)
*
|
1990-12-04 |
1997-07-01 |
H, Lundbeck A/S |
Indan derivatives
|
DE4101686A1
(de)
*
|
1991-01-22 |
1992-07-23 |
Merck Patent Gmbh |
Indolderivate
|
CZ283018B6
(cs)
*
|
1991-02-01 |
1997-12-17 |
Merck Sharp And Dohme Limited |
Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
|
US5466704A
(en)
*
|
1991-02-26 |
1995-11-14 |
E. R. Squibb & Sons, Inc. |
N-substituted imidazole and benzimidazole derivatives useful as angiotenson II antagonists
|
CA2061159A1
(en)
*
|
1991-02-26 |
1992-08-27 |
Michael A. Poss |
Imidazole and benzimidazole derivatives
|
WO1992015301A1
(en)
*
|
1991-03-01 |
1992-09-17 |
H. Lundbeck A/S |
Treatment of hypertension and peripheral vascular diseases
|
DK36291D0
(da)
*
|
1991-03-01 |
1991-03-01 |
Lundbeck & Co As H |
Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
|
DK36391D0
(da)
*
|
1991-03-01 |
1991-03-01 |
Lundbeck & Co As H |
Anvendelse af piperidylsubstituerede indolderivater til behandling af stofmisbrug
|
US5177088A
(en)
*
|
1991-04-17 |
1993-01-05 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Substituted 3-(pyridinylamino)-indoles
|
US5328920A
(en)
*
|
1991-04-17 |
1994-07-12 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Substituted (pyridinylamino)-indoles
|
US5143923B1
(en)
*
|
1991-04-29 |
1993-11-02 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Benzoisothiazole-and benzisoxazole-3-carboxamides
|
US5225412A
(en)
*
|
1991-04-29 |
1993-07-06 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Benzoisothiazole-and benzisoxazole-3-carboxamides
|
NZ243065A
(en)
*
|
1991-06-13 |
1995-07-26 |
Lundbeck & Co As H |
Piperidine derivatives and pharmaceutical compositions
|
IT1251144B
(it)
*
|
1991-07-30 |
1995-05-04 |
Boehringer Ingelheim Italia |
Derivati del benzimidazolone
|
DK206591D0
(da)
*
|
1991-12-23 |
1991-12-23 |
Lundbeck & Co As H |
Behandling af psykoser
|
US5599774A
(en)
*
|
1992-01-22 |
1997-02-04 |
Imperial Chemical Industries Plc |
N-arylindoles and their use as herbicides
|
DK8492D0
(da)
*
|
1992-01-23 |
1992-01-23 |
Lundbeck & Co As H |
Behandling af psykoser
|
DK55192D0
(da)
*
|
1992-04-28 |
1992-04-28 |
Lundbeck & Co As H |
1-piperazino-1,2-dihydroindenderivater
|
GB9210400D0
(en)
*
|
1992-05-15 |
1992-07-01 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5240927A
(en)
*
|
1992-05-19 |
1993-08-31 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
|
DE69214633T2
(de)
*
|
1992-06-19 |
1997-05-22 |
Agfa Gevaert Nv |
Thermisch übertragbare fluoreszierende Verbindungen
|
IL106445A
(en)
*
|
1992-07-30 |
1998-01-04 |
Merck Sharp & Dohme |
History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
|
US5272148A
(en)
*
|
1992-09-09 |
1993-12-21 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Heteroarenylpiperazines
|
JP3062249B2
(ja)
*
|
1993-06-25 |
2000-07-10 |
ポーラ化成工業株式会社 |
ドーパミン再取込み阻害剤
|
DK123493D0
(da)
*
|
1993-11-01 |
1993-11-01 |
Lundbeck & Co As H |
Compounds
|
DE4414113A1
(de)
*
|
1994-04-22 |
1995-10-26 |
Merck Patent Gmbh |
3-Indolylpiperidine
|
CA2157348A1
(en)
*
|
1994-09-01 |
1996-03-02 |
Aventis Pharmaceuticals Inc. |
3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
|
US5521196A
(en)
*
|
1994-10-05 |
1996-05-28 |
Eli Lilly And Company |
5-HT1F agonists for the treatment of migraine
|
US5521197A
(en)
*
|
1994-12-01 |
1996-05-28 |
Eli Lilly And Company |
3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
TR199700993T1
(xx)
*
|
1995-03-20 |
1998-03-21 |
Eli Lilly And Company |
5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
|
US5889010A
(en)
*
|
1995-05-18 |
1999-03-30 |
Pfizer Inc. |
Benzimidazole derivatives having dopaminergic activity
|
GB9523583D0
(en)
*
|
1995-11-17 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
CN1243001C
(zh)
*
|
1997-05-09 |
2006-02-22 |
H·隆德贝克有限公司 |
制造司提多尔的方法
|
AR013669A1
(es)
*
|
1997-10-07 |
2001-01-10 |
Smithkline Beecham Corp |
Compuestos y metodos
|
DE69937372T2
(de)
*
|
1999-04-21 |
2008-06-26 |
Nps Allelix Corp., Mississauga |
Piperidin-indol derivate mit 5-ht6 affinität
|
US6489341B1
(en)
|
1999-06-02 |
2002-12-03 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
|
FR2802101B1
(fr)
|
1999-12-10 |
2003-02-28 |
Aventis Pharma Sa |
Association de cymemazine et d'un neuroleptique atypique
|
US20040023951A1
(en)
*
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
US7034059B2
(en)
*
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
US7183410B2
(en)
|
2001-08-02 |
2007-02-27 |
Bidachem S.P.A. |
Stable polymorph of flibanserin
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
CA2468972A1
(en)
*
|
2001-12-10 |
2003-07-03 |
Novartis Ag |
Methods of treating psychosis and schizophrenia based on a polymorphism in the cntf gene
|
EP1478643A1
(en)
*
|
2002-02-22 |
2004-11-24 |
H. Lundbeck A/S |
5-heteroaryl substituted indoles
|
IL163992A0
(en)
*
|
2002-03-27 |
2005-12-18 |
Lundbeck & Co As H |
Method for manufacture of sertindole
|
AR039116A1
(es)
*
|
2002-03-27 |
2005-02-09 |
Lundbeck & Co As H |
Metodo para la manufactura de sertindol
|
BRPI0410271A
(pt)
*
|
2003-05-16 |
2006-05-16 |
Pfizer Prod Inc |
combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
US20050245540A1
(en)
*
|
2003-12-09 |
2005-11-03 |
Fujisawa Pharmaceutical Co., Ltd. |
New methods
|
WO2005102366A2
(en)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
AR049646A1
(es)
*
|
2004-06-16 |
2006-08-23 |
Janssen Pharmaceutica Nv |
Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
MX2007002309A
(es)
*
|
2004-08-24 |
2007-10-08 |
Johnson & Johnson |
Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
|
US20060211686A1
(en)
*
|
2005-03-18 |
2006-09-21 |
Abbott Laboratories |
Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
|
CA2609185A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Ahmed F. Abdel-Magid |
Process for preparation of sulfamide derivatives
|
CA2617546C
(en)
|
2005-08-03 |
2014-07-15 |
Boehringer Ingelheim International Gmbh |
Use of flibanserin in the treatment of obesity
|
US20070212412A1
(en)
*
|
2005-09-08 |
2007-09-13 |
H. Lundbeck A/S |
Stable solid formulation of sertindole
|
EP1945214A1
(en)
|
2005-10-29 |
2008-07-23 |
Boehringer Ingelheim International GmbH |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
AR058389A1
(es)
*
|
2005-12-19 |
2008-01-30 |
Janssen Pharmaceutica Nv |
Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8716231B2
(en)
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US8937096B2
(en)
*
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
EP2026790A2
(en)
*
|
2006-05-19 |
2009-02-25 |
Janssen Pharmaceutica, N.V. |
Co-therapy for the treatment of epilepsy and related disorders
|
TW200821296A
(en)
*
|
2006-06-01 |
2008-05-16 |
Lundbeck & Co As H |
Use of sertindole for the preventive treatment of suicidal behaviour
|
EP2041304B1
(en)
|
2006-06-12 |
2011-09-07 |
Hadasit Medical Research Services & Development Limited |
Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
|
US20080004260A1
(en)
*
|
2006-06-29 |
2008-01-03 |
Transcept Pharmaceuticals, Inc. |
Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
|
JP2009541443A
(ja)
|
2006-06-30 |
2009-11-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
尿失禁及び関連疾患の治療のためのフリバンセリン
|
CA2660476C
(en)
|
2006-08-14 |
2015-11-17 |
Boehringer Ingelheim International Gmbh |
Formulations of flibanserin and method for manufacturing the same
|
CL2007002214A1
(es)
|
2006-08-14 |
2008-03-07 |
Boehringer Ingelheim Int |
Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
|
JP5220746B2
(ja)
|
2006-08-25 |
2013-06-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
制御放出システム及びその製造方法
|
HUE032743T2
(en)
|
2006-11-22 |
2017-10-30 |
Clinical Res Ass Llc |
A method for treating Down syndrome, fragilis X syndrome and autism
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
MX2011000090A
(es)
*
|
2008-06-23 |
2011-03-02 |
Janssen Pharmaceutica Nv |
Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
|
WO2009156889A1
(en)
*
|
2008-06-25 |
2009-12-30 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
CA2686480A1
(en)
|
2008-12-15 |
2010-06-15 |
Boehringer Ingelheim International Gmbh |
New salts
|
US20100298397A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Singh Nikhilesh N |
Method of treatment of obsessive compulsive disorder with ondansetron
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
CN101591330B
(zh)
*
|
2009-06-29 |
2013-03-06 |
上海医药工业研究院 |
舍吲哚晶型及其制备方法
|
WO2012068161A1
(en)
|
2010-11-15 |
2012-05-24 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
US10154988B2
(en)
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
CN103214463A
(zh)
*
|
2013-03-30 |
2013-07-24 |
北京德众万全药物技术开发有限公司 |
一种新的舍吲哚制备方法
|
EP3083569B1
(en)
|
2013-12-20 |
2022-01-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
CA2990004C
(en)
|
2015-06-19 |
2024-04-23 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
CN104926734B
(zh)
*
|
2015-07-07 |
2017-04-05 |
苏州立新制药有限公司 |
氟班色林的制备方法
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
EA202190076A1
(ru)
|
2018-06-19 |
2021-09-22 |
Эйджинбайо, Инк. |
Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|